These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238 [TBL] [Abstract][Full Text] [Related]
46. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ; Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622 [TBL] [Abstract][Full Text] [Related]
47. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507 [TBL] [Abstract][Full Text] [Related]
48. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
49. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590 [TBL] [Abstract][Full Text] [Related]
50. [Affects of HBV genotypes (B/C) on the levels of serum and intrahepatic HBsAg]. Chen JJ; Ma SW; Wang ZH; Sun J; Zhu YF; Hou JL Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1947-51. PubMed ID: 17064586 [TBL] [Abstract][Full Text] [Related]
51. Secular trend of the viral genotype distribution in children with chronic hepatitis B virus infection after universal infant immunization. Wen WH; Chen HL; Ni YH; Hsu HY; Kao JH; Hu FC; Chang MH Hepatology; 2011 Feb; 53(2):429-36. PubMed ID: 21274864 [TBL] [Abstract][Full Text] [Related]
52. Natural history of chronic hepatitis B REVEALed. Chen CJ; Yang HI J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729 [TBL] [Abstract][Full Text] [Related]
53. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. Murakami Y; Minami M; Daimon Y; Okanoue T J Med Virol; 2004 Feb; 72(2):203-14. PubMed ID: 14695661 [TBL] [Abstract][Full Text] [Related]
54. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Yalcin K; Degertekin H; Bahcecioglu IH; Demir A; Aladag M; Yildirim B; Horasanli S; Ciftci S; Badur S Infection; 2004 Feb; 32(1):24-9. PubMed ID: 15007739 [TBL] [Abstract][Full Text] [Related]
55. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377 [TBL] [Abstract][Full Text] [Related]
56. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726 [TBL] [Abstract][Full Text] [Related]
57. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B]. Kim JM; Choe BH; Chu MA; Cho SM Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769 [TBL] [Abstract][Full Text] [Related]
58. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869 [TBL] [Abstract][Full Text] [Related]
59. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation. Wang SS; Chou NK; Chi NH; Hsu RB; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Lai MY; Chu SH Transplant Proc; 2006 Sep; 38(7):2138-40. PubMed ID: 16980024 [TBL] [Abstract][Full Text] [Related]
60. [Hepatopathy and hepatitis B virus infection in dialysis patients: cross-sectional study]. Fabrizi F; Bisegna S; Mangano S; Alongi G; Colucci P; Finazzi S; De Vecchi AF; Ponticelli C G Ital Nefrol; 2002; 19(2):149-54. PubMed ID: 12195413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]